活性位点对茴香酰化链激酶-纤溶酶原复合物（BRL 26921）的纤溶和溶栓特性研究 - Suppr

Suppr

超能文献

On the fibrinolytic and thrombolytic properties of active-site p-anisoylated streptokinase-plasminogen complex (BRL 26921).

作者信息

Matsuo O, Collen D, Verstraete M

出版信息

Thromb Res. 1981 Nov 15;24(4):347-58. doi: 10.1016/0049-3848(81)90008-6.

DOI:10.1016/0049-3848(81)90008-6

PMID:7038976

Abstract

摘要

相似文献

On the fibrinolytic and thrombolytic properties of active-site p-anisoylated streptokinase-plasminogen complex (BRL 26921).活性位点对茴香酰化链激酶-纤溶酶原复合物（BRL 26921）的纤溶和溶栓特性研究

Thromb Res. 1981 Nov 15;24(4):347-58. doi: 10.1016/0049-3848(81)90008-6.

Evidence for a sustained fibrinolytic response to anisoylated plasminogen streptokinase activator complex in vitro.体外对茴香酰化纤溶酶原链激酶激活剂复合物持续纤溶反应的证据。

Drugs. 1987;33 Suppl 3:83-7. doi: 10.2165/00003495-198700333-00012.

[Acyl enzymes and pro-urokinase: promising new thrombolytic agents].[酰基酶和前尿激酶：有前景的新型溶栓剂]

Haemostasis. 1986;16 Suppl 4:35-9. doi: 10.1159/000215530.

A comparison of acylated streptokinase-plasminogen complex and streptokinase in healthy volunteers.健康志愿者中酰化链激酶-纤溶酶原复合物与链激酶的比较。

Thromb Haemost. 1982 Apr 30;47(2):132-5.

Development and evaluation of anisoylated plasminogen streptokinase activator complex (APSAC) as a second generation thrombolytic agent.第二代溶栓剂茴香酰化纤溶酶原链激酶激活剂复合物（APSAC）的研发与评估。

J Am Coll Cardiol. 1987 Nov;10(5 Suppl B):22B-27B. doi: 10.1016/s0735-1097(87)80424-2.

Streptokinase and anisoylated streptokinase plasminogen complex. Their action on haemostasis in human volunteers.链激酶和对氨甲苯酰纤溶酶原链激酶复合物。它们对人类志愿者止血功能的作用。

Eur J Clin Pharmacol. 1983;24(6):751-6. doi: 10.1007/BF00607082.

[Anistreplase. Pharmacology and biological data].[茴酰化纤溶酶原链激酶激活剂复合物。药理学和生物学数据]

Arch Mal Coeur Vaiss. 1990 Feb;83 Spec No 1:15-20.

Acyl enzymes for thrombolytic therapy.用于溶栓治疗的酰基酶。

Semin Thromb Hemost. 1987 Apr;13(2):139-45. doi: 10.1055/s-2007-1003484.

Haematological effects of anisoylated plasminogen streptokinase activator complex and streptokinase in patients with acute myocardial infarction. Interim report of the IRS II Study.对急性心肌梗死患者使用茴香酰化纤溶酶原链激酶激活剂复合物和链激酶的血液学影响。IRS II研究中期报告。

Drugs. 1987;33 Suppl 3:247-52. doi: 10.2165/00003495-198700333-00046.

Consequences of antibody binding in vitro on the pharmacological properties of anisoylated plasminogen streptokinase activator complex.体外抗体结合对茴香酰化纤溶酶原链激酶激活剂复合物药理特性的影响。

Drugs. 1987;33 Suppl 3:64-8. doi: 10.2165/00003495-198700333-00008.

引用本文的文献

Preclinical pharmacological evaluation of anisoylated plasminogen streptokinase activator complex.茴香酰化纤溶酶原链激酶激活剂复合物的临床前药理学评价

Drugs. 1987;33 Suppl 3:33-50. doi: 10.2165/00003495-198700333-00005.

Biological study of intravenous anisoylated plasminogen streptokinase activator complex in acute myocardial infarction.静脉注射茴香酰化纤溶酶原链激酶激活剂复合物治疗急性心肌梗死的生物学研究

Drugs. 1987;33 Suppl 3:268-74. doi: 10.2165/00003495-198700333-00049.

Intravenous anisoylated plasminogen streptokinase activator complex versus intravenous streptokinase in evolving myocardial infarction. Preliminary data from a randomised multicentre study.静脉注射茴香酰化纤溶酶原链激酶激活剂复合物与静脉注射链激酶治疗进展性心肌梗死的比较。一项随机多中心研究的初步数据。

Drugs. 1987;33 Suppl 3:140-5. doi: 10.2165/00003495-198700333-00023.

Early clinical evaluation of the intravenous treatment of acute myocardial infarction with anisoylated plasminogen streptokinase activator complex.对茴香酰化纤溶酶原链激酶激活剂复合物静脉治疗急性心肌梗死的早期临床评估。

Drugs. 1987;33 Suppl 3:112-6. doi: 10.2165/00003495-198700333-00018.

Anisoylated plasminogen streptokinase activator complex (APSAC). A review of its mechanism of action, clinical pharmacology and therapeutic use in acute myocardial infarction.茴香酰化纤溶酶原链激酶激活剂复合物（APSAC）。对其作用机制、临床药理学及在急性心肌梗死中的治疗应用的综述。

Drugs. 1987 Jul;34(1):25-49. doi: 10.2165/00003495-198734010-00002.

Intravenous fibrinolytic therapy of acute myocardial infarction: new perspectives from plasminogen activators?

Klin Wochenschr. 1986 Apr 1;64(7):301-6. doi: 10.1007/BF01711946.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验